NEUROSEARCH ANNOUNCES CANCELLATION OF PHASE III TRIALS

NeuroSearch announced that its partner, Boehringer Ingelheim, has decided not to initiate Phase III clinical studies of the NS2330 compound for the treatment of Alzheimer's and Parkinson's diseases, after Phase II clinical studies did not meet the efficacy criteria.

Boehringer Ingelheim has also decided to terminate the development in the Alzheimer indication, while remaining options for Parkinson's disease are still being assessed.